Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?

被引：0
|
作者：
Avasarala, Jagannadha [1 ]
机构：
[1] Univ Kentucky Med Ctr, Dept Neurol, 740 S Limestone, Lexington, KY 40536 USA
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2024年 / 90卷 / 12期
关键词：
Anti-CD20; drugs; B cell repopulation; CD19 cell counts; COVID; 19; susceptibility; dosing frequency; multiple sclerosis; vaccine response; DEPLETION;
D O I：
10.1111/bcp.16248
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：3094 / 3096
页数：3
相关论文
共 50 条
  • [1] Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
    de Seze, Jerome
    Maillart, Elisabeth
    Gueguen, Antoine
    Laplaud, David A. A.
    Michel, Laure
    Thouvenot, Eric
    Zephir, Helene
    Zimmer, Luc
    Biotti, Damien
    Liblau, Roland
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [2] A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies
    Stoll, Sharon
    Desai, Shree
    Levit, Elle
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 71
  • [3] The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis
    Zhong, Michael
    van der Walt, Anneke
    Campagna, Maria Pia
    Stankovich, Jim
    Butzkueven, Helmut
    Jokubaitis, Vilija
    NEUROTHERAPEUTICS, 2020, 17 (04) : 1768 - 1784
  • [4] The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis
    Michael Zhong
    Anneke van der Walt
    Maria Pia Campagna
    Jim Stankovich
    Helmut Butzkueven
    Vilija Jokubaitis
    Neurotherapeutics, 2020, 17 : 1768 - 1784
  • [5] Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
    Monica Margoni
    Paolo Preziosa
    Massimo Filippi
    Maria A. Rocca
    Journal of Neurology, 2022, 269 : 1316 - 1334
  • [6] Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
    Margoni, Monica
    Preziosa, Paolo
    Filippi, Massimo
    Rocca, Maria A.
    JOURNAL OF NEUROLOGY, 2022, 269 (03) : 1316 - 1334
  • [7] Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
    Jeantin, Lina
    Abdi, Basma
    Soulie, Cathia
    Sterlin, Delphine
    Maillart, Elisabeth
    Beigneux, Ysoline
    Hippolyte, Amandine
    Belin, Lisa
    Marcelin, Anne-Genevieve
    Pourcher, Valerie
    Louapre, Celine
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024, 95 (01) : 19 - 28
  • [8] Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis
    Schiavetti, Irene
    Ponzano, Marta
    Signori, Alessio
    Bovis, Francesca
    Carmisciano, Luca
    Sormani, Maria Pia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [9] COVID-19 vaccine hesitancy in Iranian patients with multiple sclerosis
    Abbasi, Naghmeh
    Ghadiri, Fereshteh
    Moghadasi, Abdorreza Naser
    Azimi, Amirreza
    Navardi, Samira
    Heidari, Hora
    Karaminia, Maryam
    Sahraian, Mohammad Ali
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 60
  • [10] COVID-19 Vaccine intent in appalachian patients with multiple sclerosis
    Wu, Hongyan
    Ward, Melanie
    Brown, Ashlyn
    Blackwell, Erica
    Umer, Amna
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
12345